Management of the metabolic syndrome in cardiovascular disease
Tóm tắt
The main components of the metabolic syndrome (MS) are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance with or without glucose intolerance, and proinflammatory and prothrombotic states. The clustering of these metabolic risk factors significantly increases the risk of type 2 diabetes and promotes vascular endothelial dysfunction, inflammation, and increased oxidative stress. The net result is an increase in the risk of atherosclerotic cardiovascular disease. Therefore, management of MS is of utmost importance, especially considering its rapidly increasing prevalence in a population with rising obesity rates and its significant cardiovascular implications. The primary management of this syndrome involves the correction of the underlying risk factors—obesity, physical inactivity, and an atherogenic diet—with lifestyle modifications including increased physical activity and dietary modification. Smoking cessation also should be encouraged. However, pharmacologic therapies are often required to address cardiovascular risk factors. These agents can be categorized broadly into 1) anorectic agents, 2) insulinsensitizing agents, 3) statins, and 4) renin-angiotensin system antagonists. Emerging therapies include adipokines, endocannabinoid inhibitors, and metabolic modulators, such as perhexiline and trimetazidine. To date, these therapies have not been shown to normalize the metabolic and cardiovascular burden of MS, and there still is no single therapeutic agent for its management.
Tài liệu tham khảo
Webber LS, Bedimo-Rung AL: The obesity epidemic: incidence and prevalence. J La State Med Soc 2005, 157:S3–S11.
Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. A summary of the evidence. Diabetes Care 2005, 28:1769–1778.
Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359.
Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.
Grundy SM, Brewer HB Jr, Cleeman JI, et al.: Definition of metabolic syndrome: report of the American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433–438.
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002, 106:3143–3421.
Grundy SM, Cleeman JI, Daniels SR: Diagnosis and Management of the Metabolic Syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.
Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415–1428.
Eckel RH: Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic disease. Proc Nutr Soc 2007, 66:82–95.
Cersosimo E, Defronzo RA: Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006, 22:423–436.
Tooke JE, Hannemann MM: Adverse endothelial function and the insulin resistance syndrome. J Int Med 2000, 247:425–431.
Fernandez-Real JM, Ricart W: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003, 24:278–301.
Scherer PE: Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55:1537–1545.
Ingelsson E, Sullivan LM, Murabito JM, et al.: Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 2007, 56:1718–1726.
Rutter MK, Meigs JB, Sullivan LM, et al.: Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005, 54:3252–3257.
Najarian RM, Sullivan LM, Kannel WB: Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Int Med 2006, 166:106–111.
Wadden TA, Butryn ML, Wilson C: Lifestyle modification for the management of obesity. Gastroenterology 2007, 132:2226–2238.
Knowler WC, Barrett-Connor E, Fowler SE, et al.: Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.
Diabetes Prevention Program Research Group: The Diabetes Prevention Program: description of lifestyle intervention. Diabetes Care 2002, 25:2165–2171.
World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Geneva, Switzerland: World Health Organization; 1998.
Wadden TA, Butryn ML, Byrne KJ: Efficacy of lifestyle modification for long-term weight control. Obes Res 2004, 12:151S–162S.
Wadden TA, Berkowitz RI, Womble LG, et al.: Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005, 353:2111–2120.
The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096–1105. [Published erratum appears in Lancet 2006, 368:1770.]
Yki-Järvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106–1118.
Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796–2803.
Dormandy JA, Charbonnel B, Eckland DJ, et al.: PROactive Investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PRO-spective pioglitAzone Clinical Trials In macrovascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.
Raz I, Eldor R, Cernea S, Shafrir E: Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005, 21:3–14.
Onat A, Sari I, Yazici M, et al.: Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol 2006, 108:89–95.
Rosenson RS: New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Curr Probl Cardiol 2005, 30:241–279.
Keech A, Simes RJ, Barter P, et al.; FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849–1861.
Yusuf S, Sleight P, Pogue J, et al.; the Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153.
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM: Renin-angiotensin system and cardiovascular risk. Lancet 2007, 369:1208–1219.
Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201–207.
Kral JG, Näslund E: Surgical treatment of obesity. Nat Clin Pract Endocrinol Metab 2007, 3:574–583.
Fischer-Posovszky P, Wabitsch M, Hochberg Z: Endocrinology of adipose tissue—an update. Horm Metab Res 2007, 39:314–321.
Ahima RS: Central actions of adipocytes hormones. Trends Endocrinol Metab 2005, 16:307–313.
Barazzoni R, Zanetti M, Stebel M, et al.: Hyperleptinemia prevents increased plasma ghrelin concentration during short-term moderate caloric restriction in rats. Gastroenterology 2003, 124:1188–1192.
Lam KS, Xu A: Adiponectin: protection of the endothelium. Curr Diabetes Rep 2005, 5:254–259.
Fruebis J, Tsao TS, Javorschi S, et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001, 98:2005–2010.
Wallace AM, McMahon AD, Packard CJ, et al.: Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001, 104:3052–3056.
Bouloumié A, Drexler HC, Lafontan M, Busse R: Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998, 83:1059–1066.
Sánchez-Margalet V, Martín-Romero C, Santos-Alvarez J, et al.: Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol 2003, 133:11–19.
Elbatarny HS, Maurice DH: Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex. Am J Physiol Endocrinol Metab 2005, 289:E695–E702.
Tesauro M, Schinzari F, Iantorno M, et al.: Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005, 112:2986–2992.
Zigman JM, Elmquist JK: Minireview: from anorexia to obesity—the yin and yang of body weight control. Endocrinology 2003, 144:3749–3756.
Abrams CS, Ellison N, Budzynski AZ, Shattil SJ: Direct detection of activation platelet and platelet-derived microparticles in humans. Blood 1990, 75:128–138.
Broadley AJ, Gapper P, Schmitt M, Frenneaux MP: Supine rest reduces platelet activation and aggregation. Platelets 2003, 14:3–7.
Arteaga RB, Chirinos JA, Soriano AO, et al.: Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 2006, 98:70–74.
Tavil Y, Sen N, Yazici HU, et al.: Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2006, 120:245–250.
Pizzulli L, Yang A, Martin JF, Luderitz B: Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 1998, 19:80–84.
Willoughby SR, Stewart S, Holmes AS, et al.: Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2005, 25:2661–2266.
Anfossi G, Mularoni EM, Burzacca S, et al.: Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998, 21:121–126.
Smith SC Jr, Allen J, Blair SN, et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease. Circulation 2006, 113:2363–2372.
Pearson TA, Blair SN, Daniels SR, et al.: AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002, 106:388–391.
Kahraman G, Sahin T, Kilic T, et al.: The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. Int J Cardiol 2007, 115:391–396.
Serebruany VL, Miller M, Pokov AN, et al.: Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 2006, 97:1332–1336.
Cota D, Marsicano G, Tschop M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423–431.
Gelfand EV, Cannon CP: Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006, 47:1919–1926.
Cahill K, Ussher M: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007, (3):CD005353.
Lee L, Horowitz J, Frenneaux M: Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004, 25:634–641.
Ashrafian H, Horowitz JD, Frenneaux MP: Perhexiline. Cardiovasc Drug Rev 2007, 25:76–97.